This clinical trial is focused on studying the treatment of Type 2 Diabetes, a condition where the body does not use insulin properly, leading to high blood sugar levels. The study will compare two treatments: Orforglipron (also known by its code name LY3502970) and Dapagliflozin. Participants in the study will continue their current treatment with Metformin, a common medication used to help control blood sugar levels in people with Type 2 Diabetes.

The purpose of the study is to see if Orforglipron is as effective as Dapagliflozin in managing blood sugar levels. Participants will be randomly assigned to receive either Orforglipron or Dapagliflozin, both taken as capsules by mouth once a day. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient. The study will monitor changes in blood sugar levels over time to assess the effectiveness of the treatments.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable information on how well Orforglipron works compared to Dapagliflozin in people with Type 2 Diabetes who are already taking Metformin. This research could help improve treatment options for managing blood sugar levels in individuals with this condition.